Literature DB >> 35881277

Utility of Molecular Analysis of Peritoneal Fluid in Staging Laparoscopy of Advanced Esophagogastric Junction and Gastric Cancer Prior to Neoadjuvant Treatment.

M Miró1, R Vives2, L Farran2, L Secanella3, M Varela4, N Baixeras4, F Estremiana2, C Bettonica2, H Aranda2, M Galán5.   

Abstract

PURPOSE: Molecular analysis of peritoneal fluid in staging laparoscopy of gastric cancer is performed to improve the detection of free intraperitoneal tumor cells. Nevertheless, its significance is controversial, especially in patients with negative cytology but positive molecular analysis. The aim of this study was to analyze the sensitivity of molecular analysis and its prognostic value.
METHODS: A retrospective analysis from April 2011 to October 2019 was performed. Cytology (Cyt) and molecular analysis were analyzed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) of the carcinoembryonic antigen (CEA) and cytokeratin 20 (CK20) tumor makers.
RESULTS: During the study period, 138 staging laparoscopies were performed. Macroscopic carcinomatosis was found in 12.3%. Of the remaining 87.7%, 9.9% were Cyt + and 11.6% were Cyt- RT-PCR + . Of the latter, 9 responded to chemotherapy and underwent radical surgery. The sensitivity of cytology and molecular analysis was 0.70 and 0.76, respectively (p = 0.67). The 2-year overall survival (OS) of Cyt- RT-PCR + vs. Cyt + was similar (p = 0.1). The 2-year OS of Cyt-RT-PCR + subgroup who underwent radical surgery vs. Cyt-RT-PCR- patients was similar (p = 0.69), but disease-free survival was shorter in the first group (p = 0.005).
CONCLUSION: Our results show that the sensitivity of molecular analysis is similar to that of cytology. The prognostic value of positive molecular analysis was similar to positive cytology in terms of 2-year overall survival, except in the subgroup of operated patients in whom the overall survival was similar to that of those with a negative molecular analysis, albeit with a shorter disease-free survival.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cytology; Gastric adenocarcinoma; Molecular analysis; Staging laparoscopy

Year:  2022        PMID: 35881277     DOI: 10.1007/s12029-022-00846-8

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  10 in total

1.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Authors:  Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

2.  Prognostic information derived from RT-PCR analysis of peritoneal fluid in gastric cancer patients: results from a prospective multicenter clinical trial.

Authors:  Shigeyuki Tamura; Yoshiyuki Fujiwara; Yutaka Kimura; Junya Fujita; Hiroshi Imamura; Masakatsu Kinuta; Masahiko Yano; Masahiro Hiratsuka; Kenji Kobayashi; Kaoru Okada; Masaki Mori; Yuichiro Doki
Journal:  J Surg Oncol       Date:  2013-10-24       Impact factor: 3.454

3.  Seriate cytology vs molecular analysis of peritoneal washing to improve gastric cancer cells detection.

Authors:  Chiara Taffon; Isabella Giovannoni; Pamela Mozetic; Gabriella Teresa Capolupo; Vincenzo La Vaccara; Cristina Cinque; Chiara Caricato; Alberto Rainer; Giovanni Zelano; Anna Crescenzi
Journal:  Diagn Cytopathol       Date:  2019-03-01       Impact factor: 1.582

4.  Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma.

Authors:  Yasuhiro Kodera; Hayao Nakanishi; Seiji Ito; Yoshitaka Yamamura; Yukihide Kanemitsu; Yasuhiro Shimizu; Takashi Hirai; Kenzo Yasui; Tomoyuki Kato; Masae Tatematsu
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

5.  The clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids in gastric cancer with clinical serosal invasion: a prospective, multicenter study.

Authors:  Yoshiyuki Fujiwara; Kaoru Okada; Hiroyuki Hanada; Shigeyuki Tamura; Yutaka Kimura; Jyunya Fujita; Hiroshi Imamura; Kentaro Kishi; Masahiko Yano; Hirohumi Miki; Kazuyuki Okada; O Takayama; Taro Aoki; Masaki Mori; Yuichiro Doki
Journal:  Surgery       Date:  2013-10-11       Impact factor: 3.982

6.  Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.

Authors:  Shigeyuki Tamura; Hirofumi Miki; Kaoru Okada; Tomohiro Miyake; Mio Yoshimura; Rei Suzuki; Shin Nakahira; Ken Nakata; Shu Okamura; Keishi Sugimoto; Yuichi Takatsuka
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

7.  Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction.

Authors:  Kimberly Moore Dalal; Yanghee Woo; Kaitlyn Kelly; Charles Galanis; Mithat Gonen; Yuman Fong; Daniel G Coit
Journal:  Gastric Cancer       Date:  2009-01-08       Impact factor: 7.370

8.  Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer.

Authors:  Yutaka Yonemura; Yoshio Endou; Etsurou Bando; Kiyoshi Kuno; Taiichi Kawamura; Masashi Kimura; Tsutomu Shimada; Ken-Ichi Miyamoto; Takuma Sasaki; Paul H Sugarbaker
Journal:  Cancer Lett       Date:  2004-07-16       Impact factor: 8.679

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Authors:  Daniel Dindo; Nicolas Demartines; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.